Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2210202/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2210202
Jan 15, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
https://www.zacks.com/stock/news/2209160/amgen-amgn-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2209160
Jan 11, 2024 - Amgen (AMGN) reachead $303.10 at the closing of the latest trading day, reflecting a -0.48% change compared to its last close.
0
Top Stock Reports for Apple, UnitedHealth & Exxon Mobil
https://www.zacks.com/commentary/2205630/top-stock-reports-for-apple-unitedhealth-exxon-mobil?cid=CS-ZC-FT-research_daily-2205630
Jan 08, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), UnitedHealth Group Incorporated (UNH) and Exxon Mobil Corporation (XOM).
0
Here's How Much a $1000 Investment in Amgen Made 10 Years Ago Would Be Worth Today
https://www.zacks.com/stock/news/2205532/here-s-how-much-a-1000-investment-in-amgen-made-10-years-ago-would-be-worth-today?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2205532
Jan 04, 2024 - Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
0
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
https://www.fool.com/investing/2023/12/29/there-are-only-5-dow-stocks-i-wouldnt-buy-in-2024/?source=iedfolrf0000001
Dec 29, 2023 - There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.
0
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
https://www.zacks.com/stock/news/2203216/coherus-chrs-stock-rallies-on-fda-nod-for-udenyca-onbody?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2203216
Dec 28, 2023 - The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.
0
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
https://www.zacks.com/stock/news/2203052/biotech-stock-roundup-bmy-s-krtx-and-ryzb-acquisition-cytk-surges-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-2203052
Dec 28, 2023 - Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.
0
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
https://www.zacks.com/stock/news/2202718/fda-rejects-amgen-s-amgn-nda-seeking-full-nod-for-lumakras?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202718
Dec 27, 2023 - Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
0
Can Dogs of the Dow ETFs Snap Losing Trend in 2024?
https://www.zacks.com/stock/news/2200407/can-dogs-of-the-dow-etfs-snap-losing-trend-in-2024?cid=CS-ZC-FT-etf_news_and_commentary-2200407
Dec 20, 2023 - The Dogs of the Dow underperformed the broader market in 2023. However, with the Fed likely to cut rates in 2024, can these dividend dogs roar next year?
0
Amgen (AMGN) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2199629/amgen-amgn-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2199629
Dec 18, 2023 - Amgen (AMGN) reachead $275.48 at the closing of the latest trading day, reflecting a +0.01% change compared to its last close.
0